A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
NCT ID: NCT02045732
Last Updated: 2017-01-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
4 participants
INTERVENTIONAL
2014-09-30
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
NCT01803867
Safety of RG2077 in Patients With Multiple Sclerosis
NCT00076934
Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
NCT05078177
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
NCT00642902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
PF-06342674 0.25 mg/kg
Bi-Weekly Subcutaneous Injections X 6
Placebo
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 1.5 mg/kg
Placebo
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 1.5 mg/kg
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 6.0 mg/kg (q2 Weeks)
Placebo
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 6.0 mg/kg
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 6.0 mg/kg (q1 Week)
Placebo
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 6.0 mg/kg
Bi-Weekly Subcutaneous Injections X 6
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-06342674 0.25 mg/kg
Bi-Weekly Subcutaneous Injections X 6
Placebo
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 1.5 mg/kg
Bi-Weekly Subcutaneous Injections X 6
PF-06342674 6.0 mg/kg
Bi-Weekly Subcutaneous Injections X 6
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the McDonald Criteria.
* Expanded Disability Status Scale (EDSS) between 0-5, inclusive.
Exclusion Criteria
* Primary progressive MS without a relapsing component.
* Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying agents up to 6 weeks prior to enrollment.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albany Advanced Imaging
Albany, New York, United States
Fallon Wellness Pharmacy
Latham, New York, United States
Northeast Eye Center
Latham, New York, United States
The MS Center of Northeastern New York
Latham, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
Retina Vitreous Center
Edmond, Oklahoma, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Radiology Associates (X-ray facility only)
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B4351002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.